Interferon alfa-2b
- Generic Name
- Interferon alfa-2b
- Brand Names
- Intron A
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 98530-12-2
- Unique Ingredient Identifier
- 43K1W2T1M6
- Background
Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
- Indication
For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Condylomata Acuminata (External), Follicular Non-Hodgkin's Lymphoma, Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Malignant Melanoma
- Associated Therapies
- -
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2015-01-13
- Target Recruit Count
- 16
- Registration Number
- NCT01462773
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01409174
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 269
- Registration Number
- NCT01359956
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 118
- Registration Number
- NCT01274273
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Herlev University Hospital, Herlev, Denmark
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 22
- Registration Number
- NCT01217359
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2009-09-09
- Lead Sponsor
- NeoPlas Innovation
- Target Recruit Count
- 250
- Registration Number
- NCT00963664
- Locations
- 🇺🇸
NeoPlas Innovation, Nashville, Tennessee, United States
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2019-10-09
- Target Recruit Count
- 116
- Registration Number
- NCT00919633
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00629200
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of New Mexico, Albuquerque, New Mexico, United States
Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Foundation for Liver Research
- Target Recruit Count
- 30
- Registration Number
- NCT00624325
- Locations
- 🇳🇱
Erasmus University Medical Center, Rotterdam, Netherlands
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2011-12-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00561912
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.